Gem Aromatics Limited authorized the conversion of pre-existing inter-company loans into equity shares of its wholly owned subsidiary, Krystal Ingredients Private Limited. The transaction aims to strengthen the subsidiary's capital base without requiring any fresh infusion of capital from the parent company.

The Executive Committee of the Board approved the move during a meeting held on September 22, 2026. The conversion involves issuing equity shares at a price of ₹47,710 per share, comprising a face value of ₹10 and a premium of ₹47,700. Since the parent company holds 100% of the subsidiary, this transaction will not alter the existing shareholding pattern.

Transaction Details and Regulatory Compliance

The company disclosed the development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As the transaction is between a holding company and its wholly owned subsidiary, it is exempt from specific related party transaction provisions under Listing Regulations, though it remains on an arm's length basis. No governmental or regulatory approvals are required for this acquisition, which is expected to be completed within one month of requisite internal approvals.

Subsidiary Financial Performance

Krystal Ingredients Private Limited, incorporated in April 2021, is engaged in manufacturing and exporting essential oils, aroma chemicals, and specialty chemicals. The subsidiary has demonstrated significant revenue acceleration in recent fiscal years, transitioning from minimal turnover to substantial operations.

What the Numbers Show

The data reveals a sharp inflection point in Krystal Ingredients' business trajectory. Turnover surged from ₹1,111.35 thousand in FY24 to ₹3,23,296.64 thousand in FY26, indicating rapid scaling of operations. With a net worth of ₹5,98,643.63 thousand in FY26, the subsidiary maintains a robust balance sheet relative to its recent revenue growth. Converting debt to equity eliminates interest obligations on these inter-company loans, potentially improving the subsidiary's net margin profile as it continues to expand its export footprint.

Gem Aromatics Limited reported mixed financial results for the quarter ended June 30, 2026 (Q1FY27), with top-line growth contrasted by a sharp contraction in operating profitability and a consolidated net loss. Standalone revenue stood at ₹830 crore, rising 8.6% from ₹764 crore in the corresponding quarter of the previous fiscal year. However, standalone earnings before interest, taxes, depreciation and amortisation (EBITDA) fell 42.8% to ₹85 crore, down from ₹148.5 crore in Q1FY26.

The decline in operating profit led to significant margin compression. The standalone EBITDA margin for the quarter was 10.18%, compared to 16.95% in the prior year period. Despite the pressure on operating metrics, standalone net profit increased 12.3% to ₹73 crore, up from ₹65 crore in Q1FY26. On a consolidated basis, however, the company reported a net loss of ₹7.9 crore, compared to a profit in the prior year period. This divergence was driven by higher depreciation of ₹9.1 crore following the capitalization of a substantial portion of the new Dahej facility under Krystal Ingredients Private Limited.

What the Numbers Show

The divergence between revenue growth and operating profit contraction highlights margin pressure during the quarter. While topline expanded by nearly 9%, standalone EBITDA declined by over 40%, indicating that cost structures or input prices may have risen faster than sales realizations. The management attributed this to product mix shifts, higher raw material costs in the clove business due to supply disruptions in Madagascar, and the higher operating cost base of the new plant. The consolidated bottom line was further impacted by the timing mismatch where costs for the new facility kicked in before revenue from higher-margin specialty products scaled up.

Operational Updates and New Verticals

Management highlighted progress at the Dahej facility, which is moving into the next phase of operations with a focus on strengthening core customer engagement. Key updates include:

• Safranal: Commercial production has commenced. Revenue contribution is expected towards the end of Q2FY27, with meaningful contribution from Q3FY27 as commercial supplies scale up.
• Cooling Agents: Production of Gemcool 3, Gemcool 5, and Gemcool 23 has commenced. Customer audits are complete, and initial orders have been secured. Meaningful contribution is expected from Q3FY27.
• Phenol Derivatives: Trial production is expected towards the end of Q2FY27. Commercial production is targeted during Q3FY27, with meaningful revenue contribution expected from Q4FY27.

The company aims to reduce dependence on the traditional mint portfolio and build a balanced mix across non-mint and higher-value specialty products. By FY28, Krystal products are expected to contribute more than 50% of overall revenue.

Challenges and Outlook

The clove business was impacted by floods in Madagascar, affecting raw material availability and pricing. Port closures in Toamasina delayed shipments by approximately 30 days, though supply has since normalized. Management noted that demand remains strong, particularly from the Western Hemisphere, with exports ramping up as shipping challenges ease.

Looking ahead, the company expects a gradual improvement phase as newer product verticals scale up. Operating leverage is expected to support margins and profitability over the medium term as capacity utilization improves. The company has also approved the incorporation of a Brazil subsidiary to expand distribution reach in Latin America.

Earnings Call Details

Gem Aromatics hosted an investors and analysts conference call on August 14, 2026, to discuss these unaudited financial results. Senior leadership including Yash Parekh (MD & CEO) and Aadit Shah (CEO's Office) participated in the session. The transcript of the call has been filed with stock exchanges pursuant to Regulation 30 of SEBI LODR Regulations, 2015.